The DOI matches its Crossref record; 39 of the 40 references it cites were found in a registry or an index.
Downstaging Outcomes for Hepatocellular Carcinoma: Results From the Multicenter Evaluation of Reduction in Tumor Size before Liver Transplantation (MERITS-LT) Consortium
Open accessAbstract
Background & aims United Network of Organ Sharing (UNOS) has adopted uniform criteria for downstaging (UNOS-DS) of hepatocellular carcinoma (HCC) before liver transplantation (LT), but the downstaging success rate and intention-to-treat outcomes across broad geographic regions are unknown.Methods In this first multiregional study (7 centers, 4 UNOS regions), 209 consecutive patients with HCC undergoing downstaging based on UNOS-DS criteria were prospectively evaluated from 2016 to 2019.Results Probability of successful downstaging to Milan criteria and dropout at 2 years from the initial downstaging procedure was 87.7% and 37.3%, respectively. Pretreatment with lectin-reactive α-fetoprotein ≥10% (hazard ratio, 3.7; P = .02) was associated with increased dropout risk. When chemoembolization (n = 132) and yttrium-90 radioembolization (n = 62) were compared as the initial downstaging treatment, there were no differences in Modified Response Evaluation Criteria In Solid Tumors response, probability of or time to successful downstaging, waiting list dropout, or LT. Probability of LT at 3 years was 46.6% after a median of 17.2 months. In the explant, 17.5% had vascular invasion, and 42.8% exceeded Milan criteria (understaging). The only factor associated with understaging was the sum of the number of lesions plus largest tumor diameter on the last pre-LT imaging, and the odds of understaging increased by 35% per 1-unit increase in this sum. Post-LT survival at 2 years was 95%, and HCC recurrence occurred in 7.9%.Conclusion In this first prospective multiregional study based on UNOS-DS criteria, we observed a successful downstaging rate of >80% and similar efficacy of chemoembolization and yttrium-90 radioembolization as the initial downstaging treatment. A high rate of tumor understaging was observed despite excellent 2-year post-LT survival of 95%. Additional LRT to reduce viable tumor burden may reduce tumor understaging.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In patients with successful downstaging, which indirectly reflects more-favourable tumour biology, transplantation can be considered145,146.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [145]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Erdogan, D., Heijnen, B. H. M., Bennink, R. J., Kok, M., Dinant, S., Straatsburg, I. H., Gouma, D. J., & van Gulik, T. M. (2004) · Liver International · doi:10.1111/j.1478-3231.2004.00901.x · Cited by 11,656
Mazzaferro, V., Regalia, E., Doci, R., Andreola, S. A., Pulvirenti, A., Bozzetti, F., Montalto, F., Ammatuna, M., Morabito, A., & Gennari, L. (1996) · New England Journal of Medicine · doi:10.1056/nejm199603143341104 · Cited by 7,173
Acute Abdomen: A Rare Case of Ruptured Hepatocellular Carcinoma
Gloor, S., Jensen, K. O., Breitenstein, S., Binkert, C. A., Angst, E., & Hetzer, F. H. (2017) · Case Reports in Gastroenterology · doi:10.1159/000463378 · Cited by 5,370
Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma
Lencioni, R. A., & Llovet, J. M. (2010) · Seminars in Liver Disease · doi:10.1055/s-0030-1247132 · Cited by 4,354
Primary carcinoma of the liver.A study of 100 cases among 48,900 necropsies
Edmondson, H. A., & Steiner, P. E. (1954) · Cancer · doi:10.1002/1097-0142(195405)7:3 · Cited by 2,789
Clavien, P., Lesurtel, M., Bossuyt, P. M., Gores, G. J., Langer, B., & Perrier, A. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70175-9 · Cited by 1,022
Salem, R., Gordon, A. C., Mouli, S. K., Hickey, R., Kallini, J. R., Gabr, A., Mulcahy, M. F., Baker, T., Abecassis, M. M., Miller, F. H., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.08.029 · Cited by 696
Yao, F. Y., Mehta, N. J., Flemming, J. A., Dodge, J. L., Hameed, B., Fix, O. K., Hirose, R., Fidelman, N. A., Kerlan, R. K., & Roberts, J. P. (2015) · Hepatology · doi:10.1002/hep.27752 · Cited by 485
Self-citationMitchell, D. G., Bruix, J., Sherman, M., & Sirlin, C. B. (2014) · Hepatology · doi:10.1002/hep.27304 · Cited by 483
Liver transplantation for hepatocellular carcinoma: outcomes and novel surgical approaches
Sapisochín, G., & Bruix, J. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.193 · Cited by 446
Flagged first, then by citations
1 of the 40 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- Yao, 2016, Reassessing the boundaries of liver transplantation for hepatocellular carcinoma: where do we stand with tumor down-staging?, Hepatology, 63, 1014
Cited by
Sorted by citations
Items 101–154 of 154
Liver transplantation for hepatocellular carcinoma following immunotherapy
Marino, R., Hassan, A. T., Fagenson, A. M., & Tabrizian, P. (2025) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0000000000001228 · Cited by 2
Self-citationKim, M., Kang, W., Hwang, S., Ahn, C., Moon, D., Ha, T., Song, G., Jung, D., & Park, G. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11195897 · Cited by 2
Davé, S., & Esteban, J. P. (2022) · Clinical Liver Disease · doi:10.1002/cld.1258 · Cited by 2
The Role of Liver Transplantation in Hepatocellular Carcinoma
Jakhete, N., Majeed, N. A., Maluf, D. G., & Shetty, K. (2024) · Clinics in Liver Disease · doi:10.1016/j.cld.2024.08.009 · Cited by 1
Chan, K., Lai, Y., Hung, H., Lee, J., Cheng, C., Wang, Y.-C., Wu, T., Lee, C., Wu, T.-J., Chou, H., et al. (2025) · Cancers · doi:10.3390/cancers17020188 · Cited by 1
Wehrle, C. J., Kusakabe, J., Nakayama, T., Miller, C. C., Hashimoto, K., Pawlik, T. M., Sasaki, K., Mazzaferro, V., Schlegel, A. A., & Aucejo, F. (2025) · Transplantation · doi:10.1097/tp.0000000000005396 · Cited by 1
Yu, D., Li, S., Chen, H., & Wang, L. (2025) · Clinical Transplantation · doi:10.1111/ctr.70313 · Cited by 1
Expanding the path to cure - a narrative review on optimizing multimodality sequencing in HCC
Lim, H. J., Vogel, A., Dune, E. M., Brahmania, M., Tam, V. C., Abraham, R. J., Knox, J. J., Wong, J. K., Chaudhury, P. K., Ramjeesingh, R., et al. (2026) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2026.103194 · Cited by 1
Transplant oncology: Concept, history, and evolution
Mazzaferro, V., Maspero, M., & Sposito, C. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-21901-6.00001-x · Cited by 1
Sociodemographic disparities in downstaging to liver transplant for hepatocellular carcinoma
Zhou, K., Nguyen, L. A., Tabrizian, P., & Mehta, N. J. (2024) · Liver Transplantation · doi:10.1097/lvt.0000000000000532 · Cited by 1
Self-citationHepatocellular Carcinoma: Review of Indian Literature
Konda, V., & Vijayaraghavan, S. (2025) · Gastroenterology Hepatology and Endoscopy Practice · doi:10.4103/ghep.ghep_42_24 · Cited by 1
hepatocellular carcinoma and liver transplantation
Tüysüz, U. (2024) · IntechOpen eBooks · doi:10.5772/intechopen.1005591 · Cited by 1
Advanced approaches to loco-regional and surgical management for hepatocellular carcinoma
Wehrle, C. J., Archie, W., Vrochides, D. V., Schlegel, A. A., Kwon, D. C. H., & Aucejo, F. (2024) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-2024-879 · Cited by 1
Interview of John Daniel Kraus by Robert W. Wagner
Kraus, J. D. (2005) · The Knowledge Bank (The Ohio State University)
Parity and Neu oncogene activation in breast cancer risk and mammary carcinogenesis
Moody, S. E. (2003) · Scholarly Commons (University of Pennsylvania)
Liver-Directed and Systemic Therapy Options for Hepatocellular Carcinoma
Agarwal, R., Matsuoka, L. K., & Brown, D. B. (2022) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2022.5017
Braun, F., Schäfer, J. P., Dobbermann, H., Becker, T., & Linecker, M. (2023) · best practice onkologie · doi:10.1007/s11654-023-00469-w
Shaheen, M. F., Alomar, A., Alrasheed, M. A., Aldokhel, F. T., Alsaleh, A. E., Alghamdi, H., O’Hali, W., & Saad, K. B. (2023) · Experimental and Clinical Transplantation · doi:10.6002/ect.2022.0369
Marín, J. I., Saavedra-Chacón, M. F., Burbano, C. E. M., Maya, O. G. M., Santos, O. M., Hurtado, Á. M., Luna, C. E. G., Duque, S. H., Tobón-Franco, S., Gómez, J. R. M., et al. (2023) · Hepatología · doi:10.59093/27112322.170
Transarterial Chemoembolization (TACE): Indications
Crocetti, L., Scalise, P., Lorenzoni, G., & Bozzi, E. (2023) · Springer eBooks · doi:10.1007/978-3-031-36261-3_2
Liver transplantation: the recipient
(2024) · Elsevier eBooks · doi:10.1016/b978-0-443-23571-9.00034-7
Roth, B. J., Rao, S. S., Huynh, K. N., & Abi‐Jaoudeh, N. (2024) · Springer eBooks · doi:10.1007/978-3-031-52546-9_40
Анатольевна, Д. И., Новрузбеков, М. С., Олисов, О. Д., & Breder, V. V. (2024) · Bulletin of the Medical Institute REAVIZ (REHABILITATION DOCTOR AND HEALTH) · doi:10.20340/vmi-rvz.2024.2.tx.3
Harnessing the Power of Immunotherapy in Liver Transplantation for HCC
Alhaqqan, D., Khiew, Y. C., Dadashzadeh, M., He, A. R., Thomas, A. M., & Rangnekar, A. S. (2024) · Current Transplantation Reports · doi:10.1007/s40472-024-00439-3
Mohamed, I. B., Sabagh, A. E., ZainAloor, F., Talkhan, M. E., lami, Z. A., Bhongade, M., Jain, S., & Jalal, P. K. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-26711-6.00041-x
Role of immunotherapy in managing cancers prior to liver transplantation
Bredin, P., Galvin, Z., & O'Kane, G. M. (2024) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0000000000001187
Stadienabhängige Therapie beim HCC
Kobe, A. R., Heim, M., Müller, P. C., Dutkowski, P., Hess, V., & Zech, C. J. (2024) · InFo Hämatologie + Onkologie · doi:10.1007/s15004-024-0813-9
Ramachandra, S., & Rao, G. V. (2025) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2025.102548
What is the Current Treatment of Hepatocellular Carcinoma?
Martin, S. P., & Dang, H. T. (2025) · Advances in Surgery · doi:10.1016/j.yasu.2025.04.008
Tang, R., Wu, G., Li, A., Hou, Y., Tong, X., & Lü, Q. (2025) · Hepatobiliary & pancreatic diseases international · doi:10.1016/j.hbpd.2025.11.003
Liver Transplantation for Hepatocellular Carcinoma: A Comprehensive Review
Kim, S. (2025) · Convergence Hepatology · doi:10.65633/ch.2025.1.1.24
Jiang, H., Zuo, M., Wei, R., Han, J., Yao, W., Li, W., Fu, Y., Liu, W., Li, C., Lee, S., et al. (2025) · International Journal of Surgery · doi:10.1097/js9.0000000000004486
Wang, S.-Y., Sun, K., Jin, S., Wang, K.-Y., Jiang, N., Shan, S.-Q., Lu, Q., Lv, G., & Dong, J.-H. (2023) · Figshare · doi:10.6084/m9.figshare.24130163
Wang, S.-Y., Sun, K., Jin, S., Wang, K.-Y., Jiang, N., Shan, S.-Q., Lu, Q., Lv, G., & Dong, J.-H. (2023) · Figshare · doi:10.6084/m9.figshare.24130157
Wang, S.-Y., Sun, K., Jin, S., Wang, K.-Y., Jiang, N., Shan, S.-Q., Lu, Q., Lv, G., & Dong, J.-H. (2023) · Figshare · doi:10.6084/m9.figshare.24130166
Wang, S.-Y., Sun, K., Jin, S., Wang, K.-Y., Jiang, N., Shan, S.-Q., Lu, Q., Lv, G., & Dong, J.-H. (2023) · Figshare · doi:10.6084/m9.figshare.24130160
Wang, S.-Y., Sun, K., Jin, S., Wang, K.-Y., Jiang, N., Shan, S.-Q., Lu, Q., Lv, G., & Dong, J.-H. (2023) · Figshare · doi:10.6084/m9.figshare.24130169
Radioembolization for hepatocellular carcinoma
Poleo, Y. D. S., & Martínez, A. O. (2025) · Revisiones en cáncer · doi:10.20960/revcancer.00121
Duggan, E. M., Singh, N., Weeks, J. K., Talenfeld, A. D., May, B. J., Charalel, R. A., Dinmore, I., Stucky, S., Binder, T., Berman, A., et al. (2026) · Digestive Disease Interventions · doi:10.1055/a-2779-5353
ten Persigehl, T., Barabasch, A., Pereira, P. L., & Mahnken, A. H. (2026) · Die Onkologie · doi:10.1007/s00761-026-01925-2
Lehner, J., & Brunner, T. B. (2026) · Die Onkologie · doi:10.1007/s00761-026-01938-x
Ho, K. K. Y., & Chan, A. C. Y. (2026) · Artificial Intelligence Surgery · doi:10.20517/ais.2025.120
Minimally Invasive Surgery in Liver Transplantation
Ganguli, S., Khan, A. S., Wang, Y., & Cheah, Y. L. (2026) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2025.12.007
Liver Transplantation for Liver and Perihilar Neoplasms
Satyadi, M. A., Schepers, E. J., & Haugen, C. E. (2026) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2026.05.011
Sanai, F. M., Aldosari, S., Albenmousa, A. H., AlGhamdi, H. S., Alzanbagi, A., Arabi, M., Alfawaz, S., Albenmousa, F. A., Bardesi, J., Alyamani, H., et al. (2026) · ONCOLOGIE · doi:10.1515/oncologie-2026-0081
Bozzi, E., Bianchi, F., Lorenzoni, G., Giuliano, A., Scalise, P., Candita, G., Barca, P., Ambrosini, I., Boni, G., Traino, C., et al. (2026) · British Journal of Radiology · doi:10.1093/bjr/tqag155
Perioperative strategies for the treatment of HCC
D’Alessio, A., Krendl, F. J., Parente, A., Marino, R., Veloz, M. G., & Tabrizian, P. (2026) · JHEP Reports · doi:10.1016/j.jhepr.2026.102021
Self-citationLiver transplantation for primary liver cancers in the era of transplant oncology
Mazzaferro, V., Pinter, M., Pillai, A., Sposito, C., & Tabrizian, P. (2026) · Journal of Hepatology · doi:10.1016/j.jhep.2026.07.020
Self-citationCao, R., You, X., Huang, Y., Zhang, Y., Xia, F., & Cheng, Q. (2026) · Mini-invasive Surgery · doi:10.20517/2574-1225.2026.21
Huo, Y., Jiang, H., Liu, Y., Jiang, T., Ren, C., Zhang, X., Wu, B., & Tang, H. (2026) · iLiver · doi:10.1016/j.iliver.2026.100272
Immune Checkpoint Inhibitor–Based Downstaging Therapy for Hepatocellular Carcinoma
Ong, M., He, K., Wang, F., Li, Z., Pan, Y., Li, W., Fang, J., Mu, A., Li, Z., Zhong, S., et al. (2026) · JAMA Oncology · doi:10.1001/jamaoncol.2026.3901
Av, S., Drozdov, P. A., Minina, M. G., Karpov, A. A., Левина, О. Н., Astapovich, S. А., Tsurkan, V. A., Solomatin, D. A., Kurbanov, I. I., & Yurik, A. I. (2026) · Annaly khirurgicheskoy gepatologii = Annals of HPB surgery · doi:10.16931/1995-5464.2026-3-22-32
Lai, Q., Quaresima, S., Matrascia, C., & Melandro, F. (2026) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2026.2750985
Jo, Y. G., Park, Y., Lee, H.-K., Lee, S., Jung, H.-S., Choi, S. J. N., & Kim, H.-S. (2026) · Transplant International · doi:10.3389/ti.2026.17284
Metadata
- Authors
- Mehta, N., Frenette, C., Tabrizian, P., Hoteit, M., Guy, J., Parikh, N., Ghaziani, T. T., Dhanasekaran, R., Dodge, J. L., Natarajan, B., Holzner, M. L., Frankul, L., Chan, W., Fobar, A., Florman, S., & Yao, F. Y.
- Affiliations
- University of California, San Francisco (US)
- Scripps Green Hospital (US)
- Icahn School of Medicine at Mount Sinai (US)
- University of Pennsylvania (US)
- California Pacific Medical Center (US)
- University of Michigan (US)
- Stanford University (US)
- Corresponding author
- Mehta, Neil
- ORCID
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 2021-11
- Volume
- 161
- Issue
- 5
- Pages
- 1502-1512
- ISSN
- 0016-5085 (ISSN-L)
- PMC
- PMC8545832
- OpenAlex
- W3184850586
- Cited by
- 154
- References
- 40
- Citations by year
- 2026: 25 · 2025: 29 · 2024: 42 · 2023: 33 · 2022: 20 · 2021: 3
- FWCI
- 13.61
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Gastroenterology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- Exelixis
- National Institute of Diabetes and Digestive and Kidney Diseases
- Liver Center, University of California, San Francisco
- Eli Lilly and Company
- Bayer Fund
- Eisai
- National Institutes of Health (P30 DK026743)
- Genentech
- Topics
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Health Sciences › Medicine › Surgery › Organ Transplantation Techniques and Outcomes
- Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
- Keywords
- hepatocellular carcinoma, tumor downstaging, liver transplantation, Milan criteria, understaging, transarterial chemoembolization, yttrium-90 radioembolization, alpha-fetoprotein, tumor size, HCC recurrence, post-transplant survival, vascular invasion
- MeSH terms
- Aged, Feasibility Studies, Female, Carcinoma, Hepatocellular, Humans, Liver Neoplasms, Male, Middle Aged, Neoplasm Recurrence, Local, Neoplasm Staging, Patient Dropouts, Prospective Studies, Risk Factors, Time Factors, United States, Waiting Lists, Liver Transplantation, Chemoembolization, Therapeutic, Treatment Outcome, Disease Progression, Risk Assessment, Radiopharmaceuticals, Tumor Burden
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
